Fractyl Health (NASDAQ:GUTS – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Fractyl Health to related companies based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.
Profitability
This table compares Fractyl Health and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fractyl Health | N/A | -867.40% | -83.57% |
| Fractyl Health Competitors | -300.62% | -179.55% | -22.71% |
Institutional & Insider Ownership
40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 8.4% of Fractyl Health shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Fractyl Health has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500. Comparatively, Fractyl Health’s competitors have a beta of 2.58, meaning that their average share price is 158% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Fractyl Health and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fractyl Health | 1 | 1 | 3 | 0 | 2.40 |
| Fractyl Health Competitors | 4295 | 10588 | 18373 | 832 | 2.46 |
Fractyl Health currently has a consensus target price of $50.25, suggesting a potential upside of 5,461.09%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 20.55%. Given Fractyl Health’s higher possible upside, analysts plainly believe Fractyl Health is more favorable than its competitors.
Valuation and Earnings
This table compares Fractyl Health and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Fractyl Health | $90,000.00 | -$140.95 million | -0.09 |
| Fractyl Health Competitors | $1.87 billion | $136.27 million | 5.88 |
Fractyl Health’s competitors have higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Fractyl Health competitors beat Fractyl Health on 8 of the 12 factors compared.
About Fractyl Health
Fractyl Health is a clinical-stage therapeutics company focused on developing treatments for metabolic diseases, including type 2 diabetes and obesity. The company is based in Burlington, Massachusetts. Its lead program, Revita, is an investigational endoscopic procedure designed to resurface the lining of the duodenum, the first part of the small intestine. Fractyl is studying whether this approach can improve metabolic function and provide lasting benefits for people with type 2 diabetes. The company is also developing Rejuva, an experimental gene therapy platform intended to address obesity and related metabolic conditions.
Receive News & Ratings for Fractyl Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fractyl Health and related companies with MarketBeat.com's FREE daily email newsletter.
